Invention Grant
- Patent Title: Vaccine for prophylaxis or treatment of an allergen-driven airway pathology
-
Application No.: US16840276Application Date: 2020-04-03
-
Publication No.: US11110161B2Publication Date: 2021-09-07
- Inventor: Camille Locht , Bernard Mahon , Heather Kavanagh
- Applicant: Institut National de la Santé et de la Recherche Médicale (INSERM) , Institut Pasteur de Lille , National University of Ireland Maynooth
- Applicant Address: FR Paris; FR Lille; IE Maynooth
- Assignee: Institut National de la Santé et de la Recherche Médicale (INSERM),Institut Pasteur de Lille,National University of Ireland Maynooth
- Current Assignee: Institut National de la Santé et de la Recherche Médicale (INSERM),Institut Pasteur de Lille,National University of Ireland Maynooth
- Current Assignee Address: FR Paris; FR Lille; IE Maynooth
- Agent Stanley A. Kim
- Priority: EP09305371 20090428
- Main IPC: A61K39/02
- IPC: A61K39/02 ; A61P31/04 ; A61K39/00
Abstract:
The present invention relates to a live attenuated Bordetella pertussis vaccine which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT) for prophylaxis or treatment of an allergen-driven airway pathology.
Public/Granted literature
- US20200282041A1 Vaccine for Prophylaxis or Treatment of an Allergen-Driven Airway Pathology Public/Granted day:2020-09-10
Information query
